{"title":"多发性硬化症患者报告结果测量的价值。","authors":"Marisa P McGinley, Brittany Lapin","doi":"10.1177/13524585221111675","DOIUrl":null,"url":null,"abstract":"Clinical trials and regulatory agencies historically have focused on clinical outcomes including clinicianrated disability measures, biomarkers, and imaging. These outcomes often incompletely measure the experience of patients with their disease. To address these gaps, patient-reported outcome measures (PROMs) were developed to quantify the patient perspective. Although the unique benefit of PROMs has been appreciated there remains uncertainty regarding the interpretation and clinical impact of these measures.1","PeriodicalId":520714,"journal":{"name":"Multiple sclerosis (Houndmills, Basingstoke, England)","volume":" ","pages":"1489-1490"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326853/pdf/nihms-1817851.pdf","citationCount":"3","resultStr":"{\"title\":\"The value of patient-reported outcome measures for multiple sclerosis.\",\"authors\":\"Marisa P McGinley, Brittany Lapin\",\"doi\":\"10.1177/13524585221111675\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Clinical trials and regulatory agencies historically have focused on clinical outcomes including clinicianrated disability measures, biomarkers, and imaging. These outcomes often incompletely measure the experience of patients with their disease. To address these gaps, patient-reported outcome measures (PROMs) were developed to quantify the patient perspective. Although the unique benefit of PROMs has been appreciated there remains uncertainty regarding the interpretation and clinical impact of these measures.1\",\"PeriodicalId\":520714,\"journal\":{\"name\":\"Multiple sclerosis (Houndmills, Basingstoke, England)\",\"volume\":\" \",\"pages\":\"1489-1490\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326853/pdf/nihms-1817851.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multiple sclerosis (Houndmills, Basingstoke, England)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/13524585221111675\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple sclerosis (Houndmills, Basingstoke, England)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585221111675","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The value of patient-reported outcome measures for multiple sclerosis.
Clinical trials and regulatory agencies historically have focused on clinical outcomes including clinicianrated disability measures, biomarkers, and imaging. These outcomes often incompletely measure the experience of patients with their disease. To address these gaps, patient-reported outcome measures (PROMs) were developed to quantify the patient perspective. Although the unique benefit of PROMs has been appreciated there remains uncertainty regarding the interpretation and clinical impact of these measures.1
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
